About this trial
The goal of this clinical trial is to learn how GLP-1 and GIP agonists effect bowel preparation in patients scheduled for colonoscopies. The main questions it aims to answer are:
* Does GLP-1 and GIP agonist increase the rate of inadequate bowel preparation? * Does the quality of bowel preparation differ in patients who hold vs. those who continue a single dose of their GLP-1 or GIP agonist medication? * Are there any differences in the rates of complications gastric aspiration in patients who hold vs. continue a single dose of their GLP-1 or GIP agonist medication?
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Adult patient (Age 18 years or older)
Patient scheduled for outpatient screening, surveillance, or diagnostic colonoscopy
Using a GLP-1 or GIP agonist at a stable dose for at least one month
Disqualifiers
Unable to provide informed consent, e.g., dementia
Patient refuses the USMSTF recommended bowel cleansing regimen for patients with diabetes or obesity (split-dose 4 liters polyethylene glycol + 15 mg bisacodyl the afternoon before; low residue diet 3 days before colonoscopy; clear liquid diet the day before colonoscopy)
Cirrhosis
Parkinson's disease
Trial design
Parallel
Treatments tested in this trial
Continue GLP/GIP
DrugContinue GLP-1 or GIP-based therapy as prescribed prior to the procedure.
Treatment groups
Trial outcomes
Primary outcomes
Rate of inadequate bowel preparation
Secondary outcomes
Median Boston bowel prep score
Median Ottawa bowel preparation score
Adenoma detection rate
Colonoscope Insertion time
Time it takes to reach the cecum
Sponsors and contacts
Click on the lead sponsor to view all of their trials.